Dean P Hainsworth1, Ionut Bebu2, Lloyd P Aiello3, William Sivitz4, Rose Gubitosi-Klug5, John Malone6, Neil H White7, Ronald Danis8, Amisha Wallia9, Xiaoyu Gao2, Andrew J Barkmeier10, Arup Das10, Shriji Patel11, Thomas W Gardner12, John M Lachin13. 1. Mason Eye Institute, University of Missouri, Columbia, MO. 2. Biostatistics Center, The George Washington University, Washington, DC. 3. Department of Ophthalmology, Joslin Diabetes Center, Boston, MA. 4. Department of Internal Medicine, University of Iowa, Iowa City, IA. 5. Rainbow Babies and Children's Hospital, Cleveland, OH. 6. Diabetes Center, University of South Florida, Tampa, FL. 7. Pediatrics, Washington University, St. Louis, MO. 8. University of Wisconsin, Madison, WI. 9. Department of Medicine, Northwestern University, Evanston, IL. 10. University of New Mexico, Albuquerque, NM. 11. Vanderbilt University Medical Center, Nashville, TN. 12. University of Michigan Kellogg Eye Center, Ann Arbor, MI. 13. Biostatistics Center, The George Washington University, Washington, DC jml@bsc.gwu.edu.
Abstract
OBJECTIVE: The Diabetes Control and Complications Trial (DCCT) demonstrated that intensive therapy reduced the development and progression of retinopathy in type 1 diabetes (T1D) compared with conventional therapy. The Epidemiology of Diabetes Interventions and Complications (EDIC) study observational follow-up showed persistent benefits. In addition to glycemia, we now examine other potential retinopathy risk factors (modifiable and nonmodifiable) over more than 30 years of follow-up in DCCT/EDIC. RESEARCH DESIGN AND METHODS: The retinopathy outcomes were proliferative diabetic retinopathy (PDR), clinically significant macular edema (CSME), and ocular surgery. The survival (event-free) probability was estimated using the Kaplan-Meier method. Cox proportional hazards models assessed the association between risk factors and subsequent risk of retinopathy. Both forward- and backward-selection approaches determined the multivariable models. RESULTS: Rate of ocular events per 1,000 person-years was 12 for PDR, 14.5 for CSME, and 7.6 for ocular surgeries. Approximately 65%, 60%, and 70% of participants remained free of PDR, CSME, and ocular surgery, respectively. The greatest risk factors for PDR in descending order were higher mean HbA1c, longer duration of T1D, elevated albumin excretion rate (AER), and higher mean diastolic blood pressure (DBP). For CSME, risk factors, in descending order, were higher mean HbA1c, longer duration of T1D, and greater age and DBP and, for ocular surgeries, were higher mean HbA1c, older age, and longer duration of T1D. CONCLUSIONS: Mean HbA1c was the strongest risk factor for the progression of retinopathy. Although glycemic control is important, elevated AER and DBP were other modifiable risk factors associated with the progression of retinopathy.
OBJECTIVE: The Diabetes Control and Complications Trial (DCCT) demonstrated that intensive therapy reduced the development and progression of retinopathy in type 1 diabetes (T1D) compared with conventional therapy. The Epidemiology of Diabetes Interventions and Complications (EDIC) study observational follow-up showed persistent benefits. In addition to glycemia, we now examine other potential retinopathy risk factors (modifiable and nonmodifiable) over more than 30 years of follow-up in DCCT/EDIC. RESEARCH DESIGN AND METHODS: The retinopathy outcomes were proliferative diabetic retinopathy (PDR), clinically significant macular edema (CSME), and ocular surgery. The survival (event-free) probability was estimated using the Kaplan-Meier method. Cox proportional hazards models assessed the association between risk factors and subsequent risk of retinopathy. Both forward- and backward-selection approaches determined the multivariable models. RESULTS: Rate of ocular events per 1,000 person-years was 12 for PDR, 14.5 for CSME, and 7.6 for ocular surgeries. Approximately 65%, 60%, and 70% of participants remained free of PDR, CSME, and ocular surgery, respectively. The greatest risk factors for PDR in descending order were higher mean HbA1c, longer duration of T1D, elevated albumin excretion rate (AER), and higher mean diastolic blood pressure (DBP). For CSME, risk factors, in descending order, were higher mean HbA1c, longer duration of T1D, and greater age and DBP and, for ocular surgeries, were higher mean HbA1c, older age, and longer duration of T1D. CONCLUSIONS: Mean HbA1c was the strongest risk factor for the progression of retinopathy. Although glycemic control is important, elevated AER and DBP were other modifiable risk factors associated with the progression of retinopathy.
Authors: David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman Journal: N Engl J Med Date: 2005-12-22 Impact factor: 91.245
Authors: Naji Younes; Patricia A Cleary; Michael W Steffes; Ian H de Boer; Mark E Molitch; Brandy N Rutledge; John M Lachin; William Dahms Journal: Clin J Am Soc Nephrol Date: 2010-05-06 Impact factor: 8.237
Authors: Neil H White; Wanjie Sun; Patricia A Cleary; Ronald P Danis; Matthew D Davis; Dean P Hainsworth; Larry D Hubbard; John M Lachin; David M Nathan Journal: Arch Ophthalmol Date: 2008-12
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: John M Lachin; Neil H White; Dean P Hainsworth; Wanjie Sun; Patricia A Cleary; David M Nathan Journal: Diabetes Date: 2014-09-09 Impact factor: 9.461
Authors: Barbara H Braffett; Gayle M Lorenzi; Catherine C Cowie; Xiaoyu Gao; Kathleen E Bainbridge; Karen J Cruickshanks; John R Kramer; Rose A Gubitosi-Klug; Mary E Larkin; Annette Barnie; John M Lachin; David S Schade Journal: Endocr Pract Date: 2019-08-14 Impact factor: 3.443
Authors: Mark Porter; Roomasa Channa; Jessica Wagner; Laura Prichett; Tin Yan Alvin Liu; Risa M Wolf Journal: Pediatr Diabetes Date: 2020-05-31 Impact factor: 4.866
Authors: Barbara H Braffett; Rose A Gubitosi-Klug; James W Albers; Eva L Feldman; Catherine L Martin; Neil H White; Trevor J Orchard; Maria Lopes-Virella; John M Lachin; Rodica Pop-Busui Journal: Diabetes Date: 2020-02-12 Impact factor: 9.461
Authors: Ionut Bebu; Barbara H Braffett; David Schade; William Sivitz; John I Malone; Rodica Pop-Busui; Gayle M Lorenzi; Pearl Lee; Victoria R Trapani; Amisha Wallia; William H Herman; John M Lachin Journal: Diabetes Care Date: 2020-08-11 Impact factor: 19.112